Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro

Antiviral Research

Volumn 98, Issue 2, 2013, Pages 319-324

  Haasbach, Emanuel ^a   Hartmayer, Carmen ^a   Planz, Oliver ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Influenza A virus; Influenza Avirus; MEK inhibitor; Oseltamivir carboxylate; Tamiflu

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AZD 8330; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OSELTAMIVIR; RDEA 119; SELUMETINIB; SIALIDASE; SORAFENIB; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EVALUATION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS; PRIORITY JOURNAL; VACCINATION;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 84876003945     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.03.006     Document Type: Article

References (44)

1. Barrett, S.D., Bridges, A.J., Dudley, D.T., Saltiel, A.R., Fergus, J.H., Flamme, C.M., Delaney, A.M., Kaufman, M., LePage, S., Leopold, W.R., Przybranowski, S.A., Sebolt-Leopold, J., Van Becelaere, K., Doherty, A.M., Kennedy, R.M., Marston, D., Howard Jr., W.A., Smith, Y., Warmus, J.S., Tecle, H.,2008.The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD0325901.Bioorg.Med.Chem. Lett. 18,6501-6504.
2. Barrett S.D., Bridges A.J., Dudley D.T., Saltiel A.R., Fergus J.H., Flamme C.M., Delaney A.M., Kaufman M., LePage S., Leopold W.R., Przybranowski S.A., Sebolt-Leopold J., Van Becelaere K., Doherty A.M., Kennedy R.M., Marston D., Howard W.A., Smith Y., Warmus J.S., Tecle H. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 2008, 18:6501-6504.
3. Boltz, D.A., Aldridge Jr., J.R., Webster, R.G., Govorkova, E.A.,2010.Drugs in development for influenza. Drugs 70,1349-1362.
4. Boltz D.A., Aldridge J.R., Webster R.G., Govorkova E.A. Drugs in development for influenza. Drugs 2010, 70:1349-1362.
5. Chou, T.C.,2010.Drug combination studies and their synergy quantificationusing the Chou-Talalay method.Cancer Res.70,440-446.
6. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
7. Droebner, K., Pleschka, S., Ludwig, S., Planz, O.,2011.Antiviral activity of the MEK inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus invitro and invivo.Antiviral Res.92,195-203.
8. Droebner K., Pleschka S., Ludwig S., Planz O. Antiviral activity of the MEK inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res. 2011, 92:195-203.
9. Fremin, C., Meloche, S.,2010.From basic research toclinical development ofMEK1/ 2 inhibitors for cancer therapy.J.Hematol.Oncol.3,8.
10. Fremin C., Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 2010, 3:8.
11. Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D.F., Barnard, D.L., Gowen, B.B., Julander, J.G., Morrey, J.D.,2009.T-705 (favipiravir)and related compounds: novel broad-spectrum inhibitors ofRNA viral infections. Antiviral Res. 82,95-102.
12. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L., Gowen B.B., Julander J.G., Morrey J.D. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009, 82:95-102.
13. Haasbach, E., Pauli, E.K., Spranger, R., Mitzner, D., Schubert, U., Kircheis, R., Planz, O., 2011. Antiviral activity of the proteasome inhibitor VL-01 against influenzaA viruses. Antiviral Res.91,304-313.
14. Haasbach E., Pauli E.K., Spranger R., Mitzner D., Schubert U., Kircheis R., Planz O. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. Antiviral Res. 2011, 91:304-313.
15. Hayden, F.,2009.Developing new antiviral agents for influenzatreatment:what does the future hold? Clin.Infect.Dis.48(Suppl.1), S3-S13.
16. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clin. Infect. Dis. 2009, 48(Suppl. 1):S3-S13.
17. Iverson, C., Larson, G., Lai, C., Yeh, L.T., Dadson, C., Weingarten, P., Appleby, T., Vo, T., Maderna, A., Vernier, J.M., Hamatake, R., Miner, J.N., Quart, B.,2009.RDEA119/ BAY 869766: apotent, selective, allosteric inhibitor ofMEK1/2 for the treatment of cancer.Cancer Res.69,6839-6847.
18. Iverson C., Larson G., Lai C., Yeh L.T., Dadson C., Weingarten P., Appleby T., Vo T., Maderna A., Vernier J.M., Hamatake R., Miner J.N., Quart B. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009, 69:6839-6847.
19. Ludwig, S.,2009.Targeting cell signaling pathways tofightthe flu:towards a paradigm change in anti-influenzatherapy.J.Antimicrob.Chemother.64,1-4.
20. Ludwig S. Targeting cell signaling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 2009, 64:1-4.
21. Ludwig, S.,2011.Disruption of virus-host cell interactions and cell signaling pathways as ananti-viral approach against influenzavirus infections.Biol. Chem. 392,837-847.
22. Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol. Chem. 2011, 392:837-847.
23. Ludwig, S., Planz, O.,2008.Influenzaviruses and the NF-kappaB signaling pathway- towards a novel concept ofantiviral therapy.Biol.Chem.389,1307-1312.
24. Ludwig S., Planz O. Influenza viruses and the NF-kappaB signaling pathway-towards a novel concept of antiviral therapy. Biol. Chem. 2008, 389:1307-1312.
25. Pinto, R., Herold, S., Cakarova, L., Hoegner, K., Lohmeyer, J., Planz, O., Pleschka, S., 2011. Inhibition ofinfluenzavirus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and invivo.Antiviral Res.92,45-56.
26. Pinto R., Herold S., Cakarova L., Hoegner K., Lohmeyer J., Planz O., Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res. 2011, 92:45-56.
27. Planz, O., Pleschka, S., Ludwig, S.,2001.MEK-specificinhibitor U0126 blocks spread of Borna disease virus incultured cells.J.Virol.75,4871-4877.
28. Planz O., Pleschka S., Ludwig S. MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells. J. Virol. 2001, 75:4871-4877.
29. Pleschka, S.,2008.RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. Biol.Chem.389,1273-1282.
30. Pleschka S. RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. Biol. Chem. 2008, 389:1273-1282.
31. Pleschka, S., Wolff, T., Ehrhardt, C., Hobom, G., Planz, O., Rapp, U.R., Ludwig, S.,2001. Influenza virus propagation isimpaired byinhibition of the Raf/MEK/ERK signaling cascade. Nat.Cell Biol.3,301-305.
32. Pleschka S., Wolff T., Ehrhardt C., Hobom G., Planz O., Rapp U.R., Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signaling cascade. Nat. Cell Biol. 2001, 3:301-305.
33. Sebolt-Leopold, J.S.,2004.MEK inhibitors:atherapeutic approach totargeting the Ras-MAP kinase pathway intumors.Curr.Pharm.Des.10,1907-1914.
34. Sebolt-Leopold J.S. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharm. Des. 2004, 10:1907-1914.
35. Sebolt-Leopold, J.S., Herrera, R.,2004.Targeting the mitogen-activated protein kinase cascade to treat cancer.Nat.Rev.Cancer 4,937-947.
36. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
37. Solit, D.B., Garraway, L.A., Pratilas, C.A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J.M., She, Y., Osman, I., Golub, T.R., Sebolt-Leopold, J., Sellers, W.R., Rosen, N.,2006. BRAF mutation predicts sensitivity toMEK inhibition.Nature 439,358-362.
38. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
39. Tarbet, E.B., Maekawa, M., Furuta, Y., Babu, Y.S., Morrey, J.D., Smee, D.F.,2012. Combinations of favipiravir and peramivir for the treatment ofpandemic influenza A/California/04/2009 (H1N1)virus infections inmice.Antiviral Res. 94, 103-110.
40. Tarbet E.B., Maekawa M., Furuta Y., Babu Y.S., Morrey J.D., Smee D.F. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res. 2012, 94:103-110.
41. Wallace, E.M., Lyssikatos, J., Blake, J.F., Marlow, A., Greschuk, J., Yeh, T.C., Callejo, M., Marsh, V., Poch, G., Winkler, J.J., Koch, K., Davies, B.R., Wilkinson, R.W., Jones, D.C., Logie, A., McKay, J., Smith, P.D., Robinson, D.T.,2009.AZD8330 (ARRY- 424704): preclinical evaluation ofapotent, selective MEK 1/2 inhibitor currently in phase Itrails.AACR 100th Annual Meeting.Denver, USA,18th - 22nd April.
42. Wallace, E.M., Lyssikatos, J., Blake, J.F., Marlow, A., Greschuk, J., Yeh, T.C., Callejo, M., Marsh, V., Poch, G., Winkler, J.J., Koch, K., Davies, B.R., Wilkinson, R.W., Jones, D.C., Logie, A., McKay, J., Smith, P.D., Robinson, D.T., 2009. AZD8330 (ARRY-424704): preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trails. AACR 100th Annual Meeting. Denver, USA, 18th -22nd April.
43. Yeh, T.C., Marsh, V., Bernat, B.A., Ballard, J., Colwell, H., Evans, R.J., Parry, J., Smith, D., Brandhuber, B.J., Gross, S., Marlow, A., Hurley, B., Lyssikatos, J., Lee, P.A., Winkler, J.D., Koch, K., Wallace, E.,2007.Biological characterization ofARRY- 142886 (AZD6244), apotent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin.Cancer Res.13,1576-1583.
44. Yeh T.C., Marsh V., Bernat B.A., Ballard J., Colwell H., Evans R.J., Parry J., Smith D., Brandhuber B.J., Gross S., Marlow A., Hurley B., Lyssikatos J., Lee P.A., Winkler J.D., Koch K., Wallace E. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 2007, 13:1576-1583.